A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate ...
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.
GlobalData on MSN25d
Delcath’s Hepzato Kit offers better disease control than immunotherapyThe study enrolled 30 metastatic uveal melanoma patients with liver metastases who received the Hepzato Kit as either ...
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
Cholangiocarcinoma (CCA) or bile duct cancer, is a rare, aggressive liver cancer with a poor prognosis, which occurs mostly ...
News Medical on MSN5d
Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis developmentA study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
Hong Joo Kim; Kyu Taek Lee; Seung Hoon Kim; Jong Kyun Lee; Jae Hoon Lim; Seung Woon Paik; Jong Chul Rhee Extrahepatic cholangiocarcinoma is usually evident on cholangiogram, but the intrahepatic ...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...
Delcath Systems, Inc. announced the presentation of new subgroup analysis data from the phase 3 FOCUS trial of Hepzato Kit (m ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback